Drug Discovery World
JULY 20, 2023
Compounds can be printed neat at 10mM in dimethyl sulfoxide (DMSO), and a unique data point is generated per target-ligand interaction. The technique is suited for targeting proteins and structured RNA, developing heterobifunctional degrader molecules (e.g., PROTAC), and training AI drug discovery models.
Drug Discovery World
OCTOBER 4, 2022
New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 23, 2023
In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Our core technology uses machine learning (ML) models on image-based measurements of cellular morphology to broadly explore biology and chemistry and accelerate drug discovery efforts. Clinical trials revealed eight out of nine predictions were correct.
Drug Discovery World
AUGUST 15, 2023
Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods? Such techniques, if routinely deployed in drug discovery, may enable improved decision making in predicting serious adverse cardiovascular events.
Drug Discovery World
FEBRUARY 22, 2024
This article is sponsored by Collaborative Drug Discovery. Libra’s pipeline targets mechanisms that can mitigate protein pathology associated with CNS degenerative disorders. About Collaborative Drug Discovery CDD provides a modern approach to drug discovery informatics that is trusted globally by thousands of leading researchers.
Expert insights. Personalized for you.
40 
Let's personalize your content